Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 166 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Weekly Tracker

2026-08-22 to 2026-08-28
GREEN
On Track
10
Metrics in normal range
AMBER
Watch
1
Borderline or declining
RED
Alert
1
Needs attention
IMPROVING
In range
5
Week-over-week
DECLINING
Alert
5
Week-over-week

Doctor Summary - Week of 2026-08-22 to 2026-08-28

  • ATTENTION: Recovery Index is declining at 64 pts (-32.3% week-over-week)
  • Steps improved +75.1% to 6264 steps
  • REM Sleep improved +15.5% to 1.6 h
  • Readiness Score declined -5.5% to 75 pts -- monitor
  • Day 165 on ruxolitinib (started 2026-03-16)
METRICS

Metric Details

HRV (RMSSD)
30.1ms
↑ +11.1%Last week: 27.1 ms
Lowest HR
57.6bpm
↑ +3.3%Last week: 55.7 bpm
Average HR
66.7bpm
↑ +3.2%Last week: 64.7 bpm
Sleep Duration
7.4h
↓ -3.5%Last week: 7.7 h
Deep Sleep
1.6h
↑ +6.4%Last week: 1.5 h
REM Sleep
1.6h
↑ +15.5%Last week: 1.4 h
Sleep Efficiency
85%
↔ +2.8%Last week: 83 %
Readiness Score
75pts
↓ -5.5%Last week: 80 pts
Recovery Index
64pts
↓ -32.3%Last week: 95 pts
Steps
6264steps
↑ +75.1%Last week: 3578 steps
Temp Deviation
0.33°C
↑ -3.8%Last week: 0.34 °C
Breath Rate
14.9brpm
↔ +0.2%Last week: 14.9 brpm
RUXOLITINIB

Ruxolitinib Progress

Day 165 on ruxolitinib (started 2026-03-16)

MetricPre-Rux BaselineThis WeekChange
HRV (RMSSD)11.7 ms30.1 ms↑ +157.3%
Lowest HR73.0 bpm57.6 bpm↓ -21.1%
Average HR80.5 bpm66.7 bpm↓ -17.1%
Sleep Duration6.0 h7.4 h↑ +24.1%
Deep Sleep1.0 h1.6 h↑ +55.2%
REM Sleep0.8 h1.6 h↑ +87.1%
Sleep Efficiency79 %85 %↑ +7.8%
Readiness Score69 pts75 pts↑ +8.9%
Recovery Index63 pts64 pts↑ +2.4%
Steps2540 steps6264 steps↑ +146.6%
Temp Deviation0.21 °C0.33 °C↑ +59.0%
Breath Rate14.0 brpm14.9 brpm↑ +6.8%